title: Yellow Fever Vaccine Booster Doses: Recommendations of the Advisory Committee on Immunization Practices, 2015.
abstract: On February 26, 2015, the Advisory Committee on Immunization Practices (ACIP) voted that a single primary dose of yellow fever vaccine provides long-lasting protection and is adequate for most travelers. ACIP also approved recommendations for at-risk laboratory personnel and certain travelers to receive additional doses of yellow fever vaccine (Box). The ACIP Japanese Encephalitis and Yellow Fever Vaccines Workgroup evaluated published and unpublished data on yellow fever vaccine immunogenicity and safety. The evidence for benefits and risks associated with yellow fever vaccine booster doses was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework. This report summarizes the evidence considered by ACIP and provides the updated recommendations for yellow fever vaccine booster doses.
authors.forename: J Erin
authors.initials: JE
authors.lastname: Staples
authors.forename: Joseph A
authors.initials: JA
authors.lastname: Bocchini
authors.forename: Lorry
authors.initials: L
authors.lastname: Rubin
authors.forename: Marc
authors.initials: M
authors.lastname: Fischer
mesh_terms: D026683:Advisory Committees; D002648:Child; D002675:Child, Preschool; D005260:Female; D014943:Global Health / Q000331:legislation & jurisprudence; D006801:Humans; D007115:Immunization Schedule; D007117:Immunization, Secondary; D007223:Infant; D038622:Internationality; D017410:Practice Guidelines as Topic; D011247:Pregnancy; D018570:Risk Assessment; D014195:Travel; D014481:United States; D014611:Vaccination / Q000592:standards*; D015004:Yellow Fever / Q000453:epidemiology / Q000517:prevention & control*; D022341:Yellow Fever Vaccine / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology
chemical_list: D022341:Yellow Fever Vaccine